Bo Wang, Shu‐hao Hsu, Xinmei Wang, Huban Kutay, Hemant Kumar Bid, Jianhua Yu, Ramesh K. Ganju, Samson T. Jacob, Mariia Yuneva, Kalpana Ghoshal – 28 August 2013 – c‐Myc is a well‐known oncogene frequently up‐regulated in different malignancies, whereas liver‐specific microRNA (miR)‐122, a bona fide tumor suppressor, is down‐regulated in hepatocellular cancer (HCC). Here we explored the underlying mechanism of reciprocal regulation of these two genes.

Jiesi Xu, Yuanyuan Li, Wei‐Dong Chen, Yang Xu, Liya Yin, Xuemei Ge, Kavita Jadhav, Luciano Adorini, Yanqiao Zhang – 28 August 2013 – Nonalcoholic fatty liver disease (NAFLD) is one of the major health concerns worldwide. Farnesoid X receptor (FXR) is considered a therapeutic target for treatment of NAFLD. However, the mechanism by which activation of FXR lowers hepatic triglyceride (TG) levels remains unknown. Here we investigated the role of hepatic carboxylesterase 1 (CES1) in regulating both normal and FXR‐controlled lipid homeostasis.

Wan‐Ting Chen, Chun‐Chih Tseng, Kyle Pfaffenbach, Gary Kanel, Biquan Luo, Bangyan L. Stiles, Amy S. Lee – 28 August 2013 – Liver cancer is one of the most common solid tumors, with poor prognosis and high mortality. Mutation or deletion of the tumor suppressor phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is strongly correlated with human liver cancer. Glucose‐regulated protein 94 (GRP94) is a major endoplasmic reticulum (ER) chaperone protein, but its in vivo function is still emerging.

David E. Kleiner, Naga P. Chalasani, William M. Lee, Robert J. Fontana, Herbert L. Bonkovsky, Paul B. Watkins, Paul H. Hayashi, Timothy J. Davern, Victor Navarro, Rajender Reddy, Jayant A. Talwalkar, Andrew Stolz, Jiezhun Gu, Huiman Barnhart, Jay H. Hoofnagle, for the Drug‐Induced Liver Injury Network (DILIN) – 28 August 2013 – Drug‐induced liver injury (DILI) is considered to be a diagnosis of exclusion. Liver biopsy may contribute to diagnostic accuracy, but the histological features of DILI and their relationship to biochemical parameters and outcomes are not well defined.

Jurriën G.P. Reijnders, Harry L.A. Janssen – 28 August 2013

Laura James, Dean Roberts – 28 August 2013

Mariya L. Samoylova, Jennifer L. Dodge, Eric Vittinghoff, Francis Y. Yao, John Paul Roberts – 27 August 2013 – The Organ Procurement and Transplantation Network (OPTN)/United Network for Organ Sharing (UNOS) database is the most comprehensive collection of liver transplantation data, but the quality of these data with respect to hepatocellular carcinoma (HCC) recurrence has not been well assessed.

Abdl‐Rawf Al‐Nowaylati, Benjamin J. S. Al‐Haddad, Rob B. Dorman, Osama A. Alsaied, John R. Lake, Srinath Chinnakotla, Bridget M. Slusarek, Barbara K. Sampson, Sayeed Ikramuddin, Henry Buchwald, Daniel B. Leslie – 27 August 2013 – Few data are available for assessing the outcomes of bariatric surgery for patients who have undergone orthotopic liver transplantation (OLT).

Mettu Srinivas Reddy, Gomathy Narasimhan, Pradeep Thomas Cherian, Mohamed Rela – 27 August 2013

Andres Duarte‐Rojo, Vikram Budhraja, Bart J. Veldt, David D. Goldstein, Kymberly D. Watt, Julie K. Heimbach, John G. McHutchison, Hans L. Tillman, John J. Poterucha, Michael R. Charlton – 27 August 2013 – Chronic hepatitis C (CHC)–related cirrhosis is the leading indication for liver transplantation (LT). However, the recurrence of a hepatitis C virus (HCV) infection after transplantation is universal and is associated with worse outcomes.